USE OF ESTRADIOL VALERATE OR ESTRADIOL COMBINED WITH DIENOGEST FOR ORAL THERAPY OF DYSFUNCTIONAL UTERINE BLEEDING IN FORM OF ORAL CONTRACEPTIVE

摘要

PROBLEM TO BE SOLVED: To provide a mean for treating dysfunctional uterine bleeding to reduce the amount of bleeding, to prevent the recurrence of dysfunctional uterine bleeding, and at the same time, to provide a reliable and sufficiently-tolerated oral contraceptive.SOLUTION: The combination of estradiol valerate or estradiol with dienogest includes: a first phase consisting of 2 daily dose units of 3 mg of estradiol valerate or 3 mg of estradiol; a second phase consisting of 2 groups of daily dose units wherein a first group contains 5 daily dose units of a combination of 2 mg of estradiol valerate or 2 mg of estradiol with 2 mg of dienogest and a second group contains 17 daily dose units consisting of a combination of 2 mg of estradiol valerate or 2 mg of estradiol with 3 mg of dienogest; a third phase consisting of 2 daily dose units of 1 mg of estradiol valerate or 1 mg of estradiol; and an additional phase consisting of 2 daily dose units of a pharmaceutically harmless placebo.